StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Monday, March 3rd.

Can-Fite BioPharma Stock Up 4.3 %

CANF opened at $1.63 on Friday. The stock has a market capitalization of $5.77 million, a price-to-earnings ratio of -0.91 and a beta of 1.12. The company has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $1.88. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.